[CAS NO. 1564265-82-2] PS10
PRODUCTS SPECIFICATIONS [1564265-82-2]
DESCRIPTION [1564265-82-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 323.32 |
| Molecular Formula | C14H13NO6S |
| SMILES | OC1=CC(O)=CC2=C1CN(S(=O)(C3=CC=C(O)C=C3O)=O)C2 |
1 Publications Citing Use of MCE
Summary
PS10 is a novel, potent and ATP-competitive pan- PDK inhibitor, inhibits all PDK isoforms with IC 50 of 0.8 μM, 0.76 μM, 2.1 μM and 21.3 μM for PDK2, PDK4, PDK1, and PDK3, respectively. PS10 shows high affinity for PDK2 ( K d = 239 nM) than for Hsp90 (K d = 47 μM) [1] . PS10 improves glucose tolerance, stimulates myocardial carbohydrate oxidation in diet-induced obesity. PS10 has the potential for the investigation of diabetic cardiomyopathy [2] .PDK: pyruvate dehydrogenase kinase
IC50 & Target
IC50: 0.8 μM (PDK2); 0.76 μM (PDK4); 2.1 μM (PDK3); 21.3 μM (PDK1) [1]
In Vitro
PS10 shows a higher affinity of PS10 for PDK2 (K
d
= 239 nM) than for Hsp90 (K
d
= 47,000 nM)
[1]
.
PS10 is less potent than cycloheximide in HeLa cells, it shows an IC
50
value of 284 μM for the growth inhibition and PS10 has low toxicity in cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
PS10 (Intraperitoneal injection; 70 mg/kg; single dose) treatment lead to 11- and 23-fold higher PDC activity in heart and liver, respectively. Meanwhile, there results in a 1.4-fold enhancement of PDC activity in kidneys compared with vehicle-group
[1]
.
PS10 (Intraperitoneal injection; 70 mg/kg; 3 days) treatment results that thePDC activity profiles and the phospho-E1α subunit level is similar to the single-dose. Notably, the three-day treatment attenuates the enhancement of PDK activity in heart
[1]
.
PS10 (intraperitoneal injection; 70 mg/kg; 4 weeks) is treated in mice and subjected to a glucose tolerance test. when challenged with 1.5 g/kg glucose, the plasma glucose level in the vehicle-treated control is at 200 mg/dl at 0 min, peaks at 482 mg/dl at 30 min, and reduces to 210 mg/dl at 120 min. In PS10-treated DIO mice, the glucose level at 168 mg/dl at 0 min is lower than that in vehicle-treated animals, reachs 312 mg/dl at 30 min, and returns to 163 mg/dl at 120 min
[1]
.
PS10 (intraperitoneal injection; 70 mg/kg) and DCA both stimulates flux through PDC as measured by the appearance of hyperpolarized [
13
C]bicarbonate. It shows similar glucose tolerance response to glucose challenge restores PDC activity in the DIO mouse hearts
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | C57BL/6J male mice at 6 to 8 weeks old [2] |
| Dosage: | 70 mg/kg/day |
| Administration: | Intraperitoneal injection |
| Result: | Improved glucose tolerance in the intact animal. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03373175 | Corporacion Parc Tauli |
COPD
|
November 30, 2017 | Not Applicable |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 62.5 mg/mL ( 193.31 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.0929 mL | 15.4646 mL | 30.9291 mL |
| 5 mM | 0.6186 mL | 3.0929 mL | 6.1858 mL |
| 10 mM | 0.3093 mL | 1.5465 mL | 3.0929 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 6.25 mg/mL (19.33 mM); Clear solution
References
- [1] Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the ATP-binding pocket.J Biol Chem. 2014 Feb 14;289(7):4432-43.
- [2] Wu CY, et al. A novel inhibitor of pyruvate dehydrogenase kinase stimulates myocardial carbohydrate oxidation in diet-induced obesity.J Biol Chem. 2018 Jun 22;293(25):9604-9613.